2-氨基-4-(4-甲氧基苯基)-6-(哌啶-1-基)-3,5-二腈基吡啶的三组分合成与表征

在甲醇溶剂中,以丙二腈、4-甲氧基苯甲醛、哌啶为原料,常温下经三组分一锅法合成得到了未见文献报道的新化合物2-氨基-4-(4-甲氧苯基)-6-(哌啶-1-基)-3,5-二腈基吡啶,收率40%.其化学结构经过1H NMR、MS及单晶衍射进行表征.     

Serotonin 5-HT4 receptor agonistic activity of the optical isomers of (+/-)-4-amino-N-[2-(1-azabicyclo[3.3.0]octan-5-yl)ethyl]-5-chloro-2,3- dihydro-2-methylbenzo[b]furan-7-carboxamide

OBJECTIVE: To compare the influence of incongruent (asymmetric) follicular development on treatment outcome in IVF-ET and GIFT cycles. DESIGN: A retrospective comparative study. SETTING: Tertiary referral center for infertility. PATIENT(S): Five hundred forty-three consecutive assisted reproduction cycles (428 IVF-ET and 115 GIFT) in 422 infertile patients. INTERVENTION(S): Controlled ovarian hyperstimulation (COH) and IVF-ET or GIFT. MAIN OUTCOME MEASURE(S): The incongruity ratio as a parameter of the asymmetry in follicular development and pregnancy rate (PR). RESULT(S): For GIFT cycles, the PRs were 37.8% and 15.7% in cycles with congruent and incongruent follicular development, respectively. However, for IVF-ET cycles, the PR was not affected by incongruent follicular development: 28.2% and 29.0%, respectively. An inverse relationship was observed between the degree of incongruity and the estimated probability of pregnancy in GIFT cycles but not in IVF-ET cycles. Neither the side of the dominant ovary nor the degree of incongruity were consistent in consecutive cycles. CONCLUSION(S): Incongruent follicular development during COH has a significantly negative influence on the outcome of GIFT cycles but not on the outcome of IVF-ET cycles. The reason for this difference is not clear. We recommend considering IVF-ET instead of GIFT if incongruent follicular development occurs.     

Synthesis and pharmacological evaluation of 1-methyl-5-[substituted-4 (3H)-oxo-1,2,3-benzotriazin-3-yl]-1H-pyrazole-4-acetic acid derivatives

Several new 1-methyl-5-[substituted-4-oxo-1,2,3-benzotriazin-3-yl] -1H-pyrazole-4-acetic acids and their ethyl ester derivatives were prepared. The compounds were tested for analgesic and antiinflammatory activities, acute toxicity, ulcerogenic effect, and as in vitro inhibitors of 3 alpha-hydroxysteroid dehydrogenase (3 alpha-HSD), since it is claimed that the inhibition of such an enzyme predicts in vivo antiinflammatory activity. Some compounds were more active than phenylbutazone in the phenylbenzoquinone and acetic acid peritonitis tests, and equiactive to the same drug in the carrageenin paw edema test. All the compounds inhibited the 3 alpha-HSD, but no correlation was observed with the paw edema inhibition values. The compounds proved to possess marginal or no ulcerogenic effect, as well as low systemic toxicity.     

Studies on arylfuran derivatives- Part VIII. Synthesis, characterization and antibacterial activities of some 1-aminomethyl-3-substituted-4-[5-(4-nitrophenyl-2-furfurylidene)] amino-1,2,4-triazole-5-thiones

A series of 4-[5-(4-nitrophenyl-2-furfurylidene)]amino-5- mercapto-3-substituted-s-triazoles (3) and their Mannich bases (4) are synthesized. The structures of these compounds are established on the basis of elemental analysis, IR, NMR and mass spectral data. The newly synthesized compounds are screened for their antibacterial activities.     

Synthesis and in vitro microsomal metabolism of 4-ethyl-5-(4-fluorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione and its potential metabolites

Although most triazoline-3-thione derivatives (cyclic thiosemicarbazides) are important compounds possessing some biological and pharmacological activities, no literature was found showing their metabolic reactions with hepatic microsomal preparations. We, therefore, planned to study the in vitro microsomal metabolism of a prototype, 4-ethyl-5-(4-fluorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (A). The substrate (A) and its potential metabolites i.e. the corresponding dealkylation (A1), desulphuration (A2) and S-oxidation (A3) products were synthesized and characterized by spectral methods. The substrate and its potential metabolites were separated by a reverse phase HPLC. A was incubated with rat microsomal preparations fortified with NADPH and extracted into DCM; concentrated under a stream of N2 at 20 degrees C and analyzed by HPLC. The results indicated that A was metabolically inert and failed to produce the corresponding desulphuration (triazole-3-one) and S-oxidation (sulphenic acid) metabolites which would lead to pharmacological and toxicological alterations compared to the parent molecule. However, a small amount of dealkylated product (A1) was observed as a metabolite together with two unidentified metabolites.     

Study of the photochemical and phototoxic properties of lonidamine [1-(2,4-dichlorobenzyl)-1H-indazol-3-carboxylic acid

Lonidamine (LND) is an antispermatogenic and antitumour agent acting via inhibition of the energy metabolism. According to our results LND in vitro acted as a photosensitizer enhancing synergistically the lethal action of UV radiation (lambda max = 330 nm, the range between 260-390 nm) towards Ehrlich carcinoma cells (EAC). The primary targets of phototoxic action of LND probably were cell membranes and mitochondria. UV irradiation of EAC in the presence of LND increased the permeability of the plasma membranes, stimulated the photoperoxidation of lipids, enhanced the inhibition of dehydrogenase activity and oxygen consumption of the cells. Deficiency of oxygen substantially decreased phototoxicity of LND. LND may induce photosensitized destruction of biomolecules by acting through type 1 and 2 reactions. It could be supposed that negative side effects of LND (e.g., photophobia and photosensitivity that have been reported for some cancer patients treated with LND) could be associated with its photosensitizing properties.     

Urogenital anomalies in fetal rats produced by the anticancer agent 4(5)-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide

Pregnant Wistar rats injected intraperitoneally on gestational day 12 with single doses (100-1,000 mg/kg) or 600 mg/kg of 4(5)-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (dic) were autopsied on day 21 (100-1,000 mg/kg) or at 24-hour intervals on days 13-20 (600 mg/kg). Controls received CMC on the same schedule. All fetuses were weighed and examined for urogenital system (UGS) malformations. Those given 600 mg/kg were also studied histologically. DIC produced significant growth retardation at all doses on day 21 (18-72%). UGS malformations occurred in 27-67% of the fetuses at 200-400 mg/kg and in 100% of those given 600 mg/kg or more of DIC. Abnormalities included renal growth inhibition, fusion, ectopia, and ureteropelvic dilatation. At 600 mg/kg renal and body weights were reduced 40 and 55%, respectively. Ureteropelvic dilation was common, and cortical glomeruli, nephric collecting tubules, and papillae were retarded in development. The juxtamedullary glomeruli were well developed. Proximal nephric tubular mitotic activity was 85% greater than in control animals (day 17). On the basis of pertinent morphological and physiological data, it is postulated that the dilated upper urinary tracts represent functional hydronephrosis incident to severe renal retardation and its resultant compensatory response.     

Comparison of the effects of R-(-)-2-amino-1-(2,5-dimethoxy-4-methylphenyl) propane (DOM), r-(-)-2-amino-1-(2,5-dimethoxy-4-methylphenyl) butane (BL-3912A) and 5-hydroxytryptamine on non-innervated vascular smooth muscle

Human growth hormone (HGH) and somatomedin (Sm) concentrations have been studied in a group of newborns. Plasma HGH values were 41.17 +/- 24.26 (SD) ng/ml (14.00-90.00 ng/ml) and the Sm value was 0.59 +/- 0.43 (SD) U/ml (0.18-1.8 U/ml); the difference between these values and the ones observed in normal adults (2.45 +/- 2.53 (SD) ng/ml and 1.16 +/- 0.28 (SD) U/ml respectively) were statistically significant. While growth hormone values were higher than in normal adult controls, somatomedin was significantly decreased. It is possible that the dissociation between human growth hormone and somatomedin in newborn could reflect a reduced biosynthesis of the somatomedin-generating system and consequently a lack of a feed-back control on GH exerted by somatomedin.     

5—Br—PADAT和3,5—Br2—PTDAT作为络合滴定指示剂的应用

研究了５－「（５－溴－２－吡啶）偶氮」－２,４－二氨基甲苯和５－「（３,５－二溴－２－吡啶）偶氮」－２,４－二氨基甲苯作为直接滴定铜和以铜为回滴剂的批示剂的应用,以及以前者为指示剂滴定铜与锌等离子总量,并借助掩蔽剂以提高选择性,成功应用于铜合金等样品的分析。     

5-Br-PADAT和3,5-Br_2-PADAT作为络合滴定指示剂的应用

研究了 5 [(5 溴 2 吡啶 )偶氮 ] 2 ,4 二氨基甲苯和 5 [(3,5 二溴 2 吡啶 )偶氮 ] 2 ,4 二氨基甲苯作为直接滴定铜和以铜为回滴剂的指示剂的应用 ,以及以前者为指示剂滴定铜与锌等离子总量 ,并借助掩蔽剂以提高选择性 ,成功应用于铜合金等样品的分析。     

1-(4-硝基苯基)-3-(3,5-二溴吡啶)三氮烯的合成及其与铜的显色反应

合成了显色剂1-(4-硝基苯基)-3-(3,5-二溴吡啶)三氮烯(NPDBPDT),并研究了其与铜的显色反应。在pH11.0的Na2B4O7-NaOH缓冲溶液介质中,表面活性剂OP存在下,铜与NPDBPDT生成组成比为1∶4的络合物。该络合物在460nm处有最大正吸收峰,540nm处有最大负吸收峰,以540nm为参比波长,460nm为测量波长进行双波长测定络合物的吸光度。体系表观摩尔吸光系数为2.02×105L.mol-1.cm-1,铜量在8～480μg/L范围内符合比尔定律,方法检出限为7.43×10-9g/mL。所拟方法用于铜矿和铝合金样品中铜的测定,结果与原子吸收光谱法相吻合,相对标准偏差分别为1.63%和1·56%。     

Identification of two S-containing metabolites of 1-allyl-3,5-diethyl-6-chlorouracil in rabbit urine (author's transl)

The synthesis of 2-14C-1-allyl-3,5-diethyl-6-chlorouracil (2-14C-Aclu; Acluracil) is described. After application in rabbits, 2-14C-Aclu is biotransformed in one S-free major metabolite I and two S-containing minor metabolites II and III, which are more polar than Aclu. The metabolites have been isolated and purified by thick layer-, column- and gaschromatography. With the help of 1N-NMR- and mass spectroscopy, metabolite II could be identified as 1-allyl-3-ethyl-5-(2-hydroxy ethyl)-6-methylmercaptouracil and metabolite III as 1-allyl-3,5-diethyl-6-methylmercaptouracil. The introduction of methylmercapto group (-SCH3) in metabolites II and III represents a new biochemical pathway which to the best of our knowledge has not been reported in the literature up to now.     

Synthesis of the selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist (+)-(S)-2-chloro-5-methoxy-4-[5-(2-piperidylmethyl)-1,2,4-oxadiazol-3-y l]aniline

A 52-year-old white woman was first diagnosed with a tumor of the right optic nerve in 1972. She remained asymptomatic until 1992, when she had a seizure on the left side of her body from a frontoparietal glioblastoma multiforme. Ophthalmic examination revealed enlargement of the eye tumor. This case provides clinical documentation spanning 20 years of a growing, pigmented tumor of the optic nerve head shown histopathologically to be a retinal pigment epithelial adenoma.     

SK&F 96365 (1-[beta-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenylethyl]-1H- imidazole hydrochloride) stimulates phosphoinositide hydrolysis in human U373 MG astrocytoma cells

SK&F 96365 (1-[beta-[3-(4-methoxyphenyl)propoxy]-4-methoxyphenylethyl]-1H-imi dazole hydrochloride) stimulated the accumulation of [3H]inositol monophosphates ([3H]IP1) in human U373 MG astrocytoma cells prelabelled with [3H]inositol (EC50 15 +/- 1 microM, Hill coefficient 3.8 +/- 0.4). SK&F 96365-induced accumulation of [3H]IP1 increased linearly with time, but there was no initial rapid formation of [3H]IP3. SK&F 96365 also stimulated [3H]IP1 accumulation in human HeLa cells, but only to a small extent in slices of rat cerebral cortex and guinea-pig cerebellum. SK&F 96365-induced accumulation of [3H]IP1 in U373 MG cells increased as extracellular Ca2+ was increased from nominally zero to 4 mM, but there was no evidence that SK&F 96365 induced any marked entry of Ca2+ into cells; only an inhibition of store-refilling-induced Ca2+ entry was apparent. Further, the response to SK&F 96365 was additive with that to the Ca2+ ionophore ionomycin. Depolarization of the cells with raised K+ produced only a small stimulation of phosphoinositide hydrolysis. SK&F 96365 caused the release of Ca2+ from intracellular stores in U373 MG cells (EC50 26 +/- 14 microM), but thapsigargin induced only a small accumulation of [3H]IP1. Miconazole, another N-substituted imidazole, also stimulated [3H]IP1 accumulation in U373 cells.     

Preparation of 8-[3-(4-fluorobenzoyl)-propyl]-1-(4-[123I] iodobenzoyl)-1,3,8-triazaspiro[4,5]decan-4-one: a novel selective serotonin 5-HT2 receptor agent

OBJECTIVE: to evaluate the effectiveness of a reduced-frequency prenatal visit schedule by comparing perinatal outcomes, anxiety and maternal satisfaction with prenatal care. METHODS: pregnancy outcomes of infant and maternal morbidity and mortality, anxiety and satisfaction for 81 women receiving prenatal care at a free-standing birthing center according to either an alternative prenatal care visit schedule (APCVS) (n = 43) or the traditional prenatal care visit schedule (TPCVS) (n = 38) were examined in this prospective randomized study. Upon entry into prenatal care, all women were of low obstetrical risk status. RESULTS: major findings revealed no significant differences in selected perinatal outcomes between the two study groups. Women in the APCVS group reported significantly higher levels of satisfaction than women in the TPCVS group on both the satisfaction with provider subscale (F = 5.74, P = .02) and the satisfaction with the prenatal care system subscale (F = 2.01, P = .04). There were no statistically significant differences found in anxiety scores between women in the two study groups. CONCLUSIONS: low-risk women who followed the reduced-frequency visit schedule experienced no difference in perinatal outcomes or anxiety. Women in the reduced-frequency (APCVS) group reported an increased level of satisfaction with both provider and the prenatal care system.     

Studies on anti-inflammatory agents. V. Synthesis and pharmacological properties of 3-(difluoromethyl)-1-(4-methoxyphenyl)-5- [4-(methylsulfinyl)phenyl]pyrazole and related compounds

A series of novel 1,5-diphenylpyrazole derivatives bearing hydrophilic substituents was prepared. The anti-inflammatory and analgesic activities of these compounds were evaluated by using the adjuvant arthritis and Randall-Selitto assays in rats, and the structure-activity relationships were studied. The optimal compound was 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-[4-(methylsulfinyl)phenyl]pyraz ole (10) with oral ED50 values of 0.31 and 2.6 mg/kg on adjuvant-induced arthritis and carrageenin-induced foot edema, respectively. Compound 10 showed analgesic activities not only toward inflamed paw but also toward normal paw (ED30 = 0.55 and 1.8 mg/kg, respectively) in the Randall-Selitto assay, and moreover, 10 was effective in the tail-pinch assay (ED50 = 21 mg/kg) similarly to morphine. The asymmetric synthesis and pharmacological properties of the enantiomers of 10 are also reported.     

Studies of the antagonist actions of (RS)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl] propionic acid (ATPO) on non-NMDA receptors in cultured rat neurones

Whole-cell patch-clamp recordings from single cultured cortical neurones have been used to study the action of (RS)-2-amino-3-[5-tert-butyl-3-(phosphonomethoxy)-4-isoxazolyl+ ++]propionic acid (ATPO), which has previously been proposed to be a potent selective antagonist of 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA) receptors. ATPO competitively reduced peak responses evoked by semi-rapid applications of AMPA (Ki = 16 microM) but had variable effects on plateau responses, which were on average unchanged. Following blockade of AMPA receptor desensitization by cyclothiazide (CTZ, 100 microM), the plateau responses were reduced by ATPO to a similar extent as the peak responses, indicating that ATPO reduces desensitization of AMPA receptors. Semi-rapid application of kainic acid (KA) and the KA receptor-selective agonist, (2S,4R)-4-methylglutamic acid (MeGlu) evoked non-desensitizing responses which were competitively antagonized by ATPO (Ki values: 27 and 23 microM, respectively). Responses to MeGlu were unaffected by CTZ (100 microM), but potentiated 3 fold following blockade of KA receptor desensitization by concanavalin A (Con A, 300 microg ml(-1)). Responses of spinal cord neurones to MeGlu were blocked by ATPO to a similar extent before and after blockade of KA receptor desensitization by Con A. Although selectively potentiated by Con A, plateau responses to MeGlu were reduced by 69.6% by the AMPA selective antagonist, GYKI 53655 (10 microM). The remaining component was further reduced by ATPO with a Ki of 36 microM, which was not significantly different from that in the absence of GYKI 53655, but was greater than that on responses to AMPA. It is concluded that ATPO is a moderate-potency competitive inhibitor of naturally expressed non-NMDA receptors.